Chinese
Home
About Livzon
Chairman's Speech
Milestones
Leaders' Caring
Company Honors
Cultural Vision
Contact Us
Media
Livzon News
Employment system
Investor Relations
Company Governance
Announcement
Financial Reports
ESG Report
Shareholder Returns
Stock Information
Sustainable Development
Human Development
Board Diversity Policy
Business Ethics
Supplier
Environment, Occupational Health and Safety (EHS)
Philanthropy
Privacy Policy
Tax policy
ESG Ratings and Honors
Product
Leading Products
Products List
ADR Reporting
R&D
R&D Platforms
Livzon microspheres
Livzon Bio
Livzon Research Institute
R&D Achievements
IP Achievements
Overseas Market
Overseas Business
Specialty Products
Certificates
Contact us
Join Us
Social Recruitment
Campus Recruitment
Compensation and Benefits
Appeal Against
Bidding procurement
Tender Announcement
Supplier Login
Supervision and Reporting
Contact information
Online message
Bismuth Potassium Citrate Tablets
Key words:
LIVZON
Antiviral Granules
Cetrorelix Acetate for Injection
Tocilizumab Injection
Recombinant Human Choriogonadotropin alfa for Injection
the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01
Active pharmaceutical ingredients
Quality supervisor
Latest News
The new generation of high-efficiency acid-inhibiting agent injection JP-1366 by Livzon has been approved for clinical use.
Good news frequently arrives | Livzon Group's clinical trial application for injectable JP-1366 has been accepted by the National Medical Products Administration's Drug Evaluation Center.
Research and innovation also speed up the progress bar | Livzon Group JP-1366 Phase III clinical study launched
Livzon Group's Semaglutide Injection has completed the enrollment of all cases in the Phase III clinical trial for weight management indications.
Livzon and Neosun jointly announced: The Phase I clinical trial of KCNQ2/3 activator (NS-041) has been successfully completed.
Once again on the list! Livzon Group has been selected as one of the "Top 100 ESG Best Practices of Chinese Listed Companies in 2024" by Wind.